Bioventix (LON:BVXP) Shares Down 2.6% - What's Next?

Bioventix PLC (LON:BVXP) experienced a decline of 2.6% in mid-day trading on Friday. The stock price fell to as low as GBX 3,450 ($43.54) and was last seen trading at GBX 3,456 ($43.62). In total, approximately 7,664 shares were exchanged during the trading session, marking a 31% increase from the average daily volume of 5,833 shares. The stock had closed the previous day at GBX 3,550 ($44.81).

Bioventix Stock Performance

The company has a market cap of £180.40 million and reports a price-to-earnings ratio of 2,120.25. Additionally, Bioventix has a beta of 0.35, indicating relatively stable performance in relation to market fluctuations. The fifty-day moving average price stands at GBX 3,712.29, while the 200-day moving average price is GBX 4,034.04.

Bioventix Increases Dividend

Recently, Bioventix declared a dividend that was distributed on November 21st. Shareholders recorded on November 7th received a dividend payout of GBX 87 ($1.10) per share, which is an increase from the company's previous dividend of GBX 68. This change reflects a yield of 2.4%, although the dividend payout ratio appears extraordinarily high at 9,693.25%.

Insider Activity

In other company news, insider Bruce Hiscock purchased 24 shares of Bioventix stock on November 22nd at an average price of GBX 3,822 ($48.24). The total value of this transaction was £917.28 ($1,157.74). Corporate insiders hold about 8.02% of the company's stock.

About Bioventix

Bioventix PLC specializes in creating, manufacturing, and supplying sheep monoclonal antibodies (SMAs) for diagnostic purposes worldwide. The company offers a diverse range of purified SMAs used in diagnostics for thyroid conditions, vitamin D, cardiac health, drug abuse tests, fertility, oncology, and more. Additionally, they provide the Pyrene (HOP-G) ELISA kit, which is designed for monitoring human exposure to industrial pollutants.

Should You Sell Bioventix Stock?

Given the recent stock decline, potential investors may be contemplating whether it's time to sell or hold onto their shares. Analysts currently assign a "Hold" rating for Bioventix. However, some top analysts have identified five different stocks that they believe are more promising investments at this time. Investors should carefully consider their options and may want to explore these alternative stock opportunities.

stocks, dividend, insider